RecruitingNCT03549416

BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis

BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Diseases in Daily Practice

Sponsor

UMC Utrecht

Enrollment

1,200 participants

Start Date

Jan 1, 2018

Study Type

OBSERVATIONAL

Conditions

Atopic Dermatitis

Summary

The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.

Eligibility

Min Age: 0 Years

Inclusion Criteria1

All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry

Exclusion Criteria1

Patients are not eligible for enrolment in case of presumed inability to answer questionnaires or not willing to answer questionnaires and will be excluded.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(14)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

Isala Dermatologisch Centrum

Zwolle, Overijssel, Netherlands

Medisch Centrum Leeuwarden

Leeuwarden, Provincie Friesland, Netherlands

University Medical Center Groningen

Groningen, Provincie Groningen, Netherlands

IJsselland Ziekenhuis

Capelle aan den IJssel, South Holland, Netherlands

University Medical Center Utrecht

Utrecht, Utrecht, Netherlands

Meander Medisch Centrum

Amersfoort, Netherlands

Reinier de Graaf ziekenhuis

Delft, Netherlands

Catharina ziekenhuis

Eindhoven, Netherlands

Spaarne Gasthuis

Haarlem, Netherlands

Maastricht Univeristy Medical Center

Maastricht, Netherlands

Haga ziekenhuis

The Hague, Netherlands

Diakonessenhuis

Utrecht, Netherlands

St Antonius ziekenhuis

Utrecht, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03549416

Related Trials

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

NCT072629831 location

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

NCT0599596498 locations

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

NCT0700342545 locations

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT0729080343 locations

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT0727766050 locations